Get to know our clinical trials
Trial of Onabotulinumtoxin A injection into the corpora cavernosa in patients with erectile dysfunction refractory to treatment with phosphodiesterase-5 inhibitors.
THIS STUDY AIMS AT THE DEVELOPMENT OF AN EFFECTIVE, SAFE AND LONG-LASTING TREATMENT FOR ERECTILE DYSFUNCTION, ESPECIALLY FOR REFRACTORY VASCULOGENIC ERECTILE DYSFUNCTION, WHICH IS AN UNMET MEDICAL NEED.
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- RANDOMIZED DOUBLE-BLIND CLINICAL STUDY OF ONABOTULINUMTOXIN A INJECTION INTO THE CORPORA CAVERNOSA IN PATIENTS WITH ERECTILE DYSFUNCTION REFRACTORY TO TREATMENT WITH PHOSPHODIESTERASE-5 INHIBITORS
- Code EudraCT: 2024-514518-10-00
- Protocol number: BTXDE
- Promoter: CUN
- Molecule/Drug: Onabotulinumtoxina A
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.